Orthopedic :: Drug eluting nanostructured coatings enable targeted drug therapy for orthopedic patients
Drug delivery systems have progressed from the teaspoon to time-release capsules to drug-eluting stents.
Therapy
Hepatitis C :: Retrospective Analysis of the Effect of Taking a Statin Along with Peginterferon and Ribavirin
Researchers retrospectively analyzed the effect of taking peginterferon and ribavirin (PI+R, hepatitis C treatment options) and PI+R plus a statin to measure the sustained viral response (SVR, negative virus in blood six months after the end of treatment) rate in hepatitis C patients.
Hepatitis C :: Statins Improve ALT Values in Chronic Hepatitis C Patients
Researchers have yet to report on the concept that hepatitis C virus (HCV) patients who take statins may experience improvements in alanine transaminase (ALT, liver enzymes) levels.
Hepatitis C :: Could statins be a new option for hepatitis C patients?
Research presented at Digestive Disease Week? 2007 (DDW?) demonstrates the potential of statins, important cholesterol management therapies, for improving the management of hepatitis C ? a disease that affects nearly four million Americans.
Prostate Cancer :: Intermittent androgen deprivation in patients with PSA-relapse after radical prostatectomy
In men with PSA relapse following prostatectomy, androgen deprivation is commonly used to slow tumor progression.
Hepatitis C :: Use of Hepatitis C-Infected Donors in Liver Transplantation
To meet the increasing demand for donor livers, researchers are searching for opportunities to utilize non-optimal livers to offer some improvement to severely ill patients.
Cancer :: Nanocomposite labeled cancer cells can be targeted and destroyed using lasers
A nanocomposite particle can be constructed so that it has a mix of properties that would not otherwise happen in nature. By combining an organic matrix with metallic clusters that can absorb light, it is possible to incorporate such particles into cells and then destroy those targeted cells with a laser.
Cancer :: Targeted nanoparticles incorporating siRNA offer promise for cancer treatment
The use of targeted nanoparticles offers promising techniques for cancer treatment. Researchers in the laboratory of Mark E. Davis at the California Institute of Technology have been using small interfering RNA (siRNA), sometimes known as silencing RNA, to “silence” specific genes that are implicated in certain malignancies.
NHS :: 100’s more health projects to boost NHS at local level
People across the UK country will benefit from hundreds of new health services over the next twelve months Patricia Hewitt said.
Hepatitis C :: Schering-Plough presenting Hepatitis C at Digestive Disease Week 2007 Annual Meeting
A total of 20 oral and poster presentations on clinical studies with Schering-Plough’s hepatitis products, including PEGINTRON(TM) (peginterferon alfa-2b) and REBETOL(R) (ribavirin, USP) combination therapy for chronic hepatitis C virus (HCV) infection, as well as boceprevir (SCH 503034), the company’s investigational oral HCV protease inhibitor currently in Phase II clinical development, will be presented by leading researchers at the 38th annual Digestive Disease Week (DDW) meeting to be held at the Washington Convention Center in Washington, D.C., May 20-23.